Five Common Symptoms Of Stomach Cancer That Should Not Be Ignored

Updated Dec 13, 2024 | 02:53 PM IST

SummaryStomach or gastric cancer is a type of cancer that develops in the lining of the stomach. There are certain symptoms like vomiting blood, abdominal pain that should immediately be addressed.
Stomach cancer

Stomach cancer (credit: canva)

Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).

A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:

1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.

2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.

3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.

4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.

5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding

There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.

How Does Stomach Cancer Spread?

Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.

1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.

2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.

3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.

He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.

End of Article

White House Drops Heidi Overton’s Nomination For US FDA Chief

Updated Nov 18, 2026 | 10:58 AM IST

SummaryHeidi Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.
White House Drops Heidi Overton’s Nomination For US FDA Chief

Credit: AP Photos

The White House has withdrawn the nomination of physician and presidential adviser Dr. Heidi Overton to lead the Food and Drug Administration (FDA), ending her bid for the top regulatory post just a day before a scheduled Senate committee vote.

Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.

“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy wrote on X shortly after the withdrawal.

A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.”

Republican Opposition Threatened Her Confirmation

Also read: Meet Heidi Overton: Trump Set to Nominate White House Adviser to Lead FDA

The nomination faced growing resistance from Republican members of the 21-member Senate committee. Overton needed the support of all 12 Republicans to advance, assuming all 11 Democrats voted against her.

Several Republican senators had not committed to supporting her, including Cassidy, Susan Collins and Lisa Murkowski. The uncertainty left the White House struggling to secure the votes needed ahead of the November 18 committee hearing.

Cassidy, however, maintained that Overton was close to securing enough support. Calling the withdrawal “odd,” he said he had been having productive conversations with senators and believed she could have cleared both the committee and the full Senate.

What Went Wrong For Dr. Heidi Overton?

Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation

Overton faced opposition over her positions on vaccine policy, abortion medication and vaping, exposing divisions among Republicans and the MAHA movement.

Vaccine policy: Cassidy questioned her role in Trump's efforts to change childhood vaccine recommendations, including splitting the combined measles, mumps and rubella (MMR) vaccine. Overton maintained that the MMR vaccine was safe and effective and said she would follow FDA safety requirements.

Mifepristone restrictions: Anti-abortion groups and Republican Sen. Josh Hawley questioned her commitment to tightening restrictions on mifepristone, the abortion pill. Meanwhile, Republican senators Susan Collins and Lisa Murkowski raised concerns about her strong anti-abortion positions.

Flavoured vapes: Overton faced criticism for her role in the administration's authorisation of fruit-flavoured e-cigarettes. Opponents even launched a campaign using the label “Heidi Vaperton” to urge senators to reject her nomination.

MAHA backlash: Some supporters of Robert F. Kennedy Jr.'s Make America Healthy Again movement accused Overton of being too close to corporate and agricultural interests. Former White House adviser Calley Means alleged that her decisions on glyphosate and flavoured vapes conflicted with Kennedy's agenda.

Who Is Dr. Heidi Overton?

Overton is a physician and former deputy director of the White House Domestic Policy Council. Before her nomination, she worked at the conservative think tank America First Policy Institute, where she eventually led its Health Policy Center.

She received her medical degree from the University of New Mexico, completed general surgery training at Johns Hopkins University and pursued clinical investigation research training at the Johns Hopkins Bloomberg School of Public Health.

She also served during Trump's first administration before joining the think tank.

Overton was involved in several prominent health policy initiatives under the current administration, including efforts to redesign the food pyramid, overhaul childhood vaccine recommendations and negotiate prescription drug pricing deals.

FDA Continues Under Acting Leadership

The withdrawal leaves the FDA without a Senate-confirmed commissioner. Acting Commissioner Kyle Diamantas has been leading the agency since Makary resigned in May.

The administration is now considering potential replacements, including Republican Senator Roger Marshall of Kansas, according to Reuters. No new nominee has been formally announced.

End of Article

Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

Updated Nov 18, 2026 | 09:34 AM IST

SummarySELLAS Life Sciences recently announced findings from their late-stage clinical trial in which they tested an experimental cancer vaccine for acute myeloid leukemia (AML).
Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

Credit: AI image

Amid growing research in vaccination for different cancers, an experimental cancer vaccine cut the risk of death by 41% in patients with acute myeloid leukemia (AML) in a late-stage clinical trial.

Showing promise in treating the aggressive blood cancer, the findings have given hope to patients whose cancer has returned after treatment and those who have limited options.

The vaccine, called galinpepimut-S (GPS), is being developed by US-based pharma company SELLAS Life Sciences. Results from the Phase 3 REGAL trial showed that patients who received the vaccine lived longer than those given the next best available treatment.

What Is Acute Myeloid Leukemia?

Also read: Health Canada Warns Against Faulty Radon Detectors: How The Invisible Gas In Your Home May Cause Lung Cancer

Acute myeloid leukemia is an aggressive blood cancer that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. It develops when abnormal immature blood cells multiply rapidly and interfere with the production of healthy red blood cells, white blood cells and platelets.

Common symptoms include persistent fatigue, fever, frequent infections, easy bruising, unusual bleeding and breathlessness.

Treatment usually involves chemotherapy, specific medicines in eligible patients and in some cases, stem-cell transplantation. AML can return after treatment, making it difficult to achieve remission.

What Did The Trial Find?

Also read: World Cervical Cancer Elimination Day 2026: WHO Calls For HPV Vaccination, Screening & Early Treatment

The trial involved 126 patients who had achieved remission after treatment but were unable to undergo a stem-cell transplant.

According to the findings, the vaccine reduced the risk of death by 41%. Patients receiving GPS had a median overall survival of 24 months, compared to 14.7 months among those receiving standard treatment. The results also showed a hazard ratio of 0.59 and a p-value of 0.035.

SELLAS plans to discuss the findings with the US Food and Drug Administration (FDA), preparing to submit an application for approval in the first half of 2027.

How Does The Leukemia Vaccine Work?

Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Unlike preventive vaccines, GPS is a therapeutic cancer vaccine. It is developed to help immune system identify and destroy residual cancer cells in the body after treatment.

The vaccine targets a protein called Wilms' Tumour 1 (WT1), which is found in more than 95% of people with AML, according to Memorial Sloan Kettering Cancer Center (MSK), where the vaccine was developed.

GPS contains synthetic peptides, which are short chains of amino acids derived from the WT1 protein. These peptides help the immune system to produce specialised T cells that recognise and attack cancer cells carrying WT1.

In simple terms, the vaccine trains the immune system to identify leftover cancer cells that may be too small to detect through routine testing but could eventually cause cancer recurrence.

Unlike personalised cancer vaccines that are manufactured using an individual patient's tumour, GPS is an off-the-shelf vaccine that can be used in multiple patients.

Side Effects Of GPS

GPS was generally tolerated well in the Phase 3 trial as no safety concerns were identified. Most side effects were mild to moderate. Reactions at injection sites were among the most commonly reported side effects.

The company, however, has only announced topline results. The detailed findings from the trial's secondary endpoints related to relapse-free and leukemia-free survival, will be presented at a future medical conference.

If the findings are supported by regulatory authorities, GPS could become a new treatment option for patients whose AML has relapsed and those who cannot opt for a stem-cell transplant.

End of Article

Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

Updated Nov 18, 2026 | 08:53 AM IST

SummaryThe Pan American Health Organization (PAHO) recently announced that the United States, Mexico and Bolivia have lost their measles-free status as they failed to interrupt transmission over a period of 12 months.
Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

Credit: AI image

The United States is not the only country to lose its measles elimination status this year. Mexico and Bolivia have also lost the status after the highly contagious virus continued spreading for more than 12 months, according to the Pan American Health Organization (PAHO).

The decision was formally announced on November 17, 2026 by PAHO's independent Regional Monitoring and Re-Verification Commission, which reviewed measles data from 47 countries and territories across the Americas.

The United States had maintained its measles elimination status since 2000, while Mexico and Bolivia had also previously interrupted sustained local transmission. The latest development marks a setback in efforts to control a disease that can be prevented through vaccination.

The announcement comes as measles cases continue to rise across the region. As of November 13, 2026, the Americas had reported 58,213 confirmed cases and 82 deaths, compared with 12,806 cases during the same period in 2025.

Three Countries In Americas Lose Measles-Free Status

Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

According to PAHO, a country loses its measles elimination status when the same measles virus genotype and lineage circulates continuously within its borders for at least 12 months. This indicates that the virus has re-established endemic transmission rather than appearing only through isolated cases imported from other countries.

According to PAHO, the sustained transmission periods in the three countries began on different dates:

  • United States: The outbreak began on January 20, 2025, reaching the 12-month threshold on January 20, 2026.
  • Mexico: The outbreak began on February 1, 2025, reaching the one-year mark on February 1, 2026.
  • Bolivia: The outbreak began on April 16, 2025, marking one year of continued transmission on April 16, 2026.

Losing elimination status does not mean that measles is spreading everywhere within these countries. It means that the same virus lineage has continued circulating locally for at least a year.

The Americas had previously lost its regional measles elimination status in November 2025, after Canada reported to have sustained transmission for more than 12 months. The region had first eliminated measles in 2016 and regained that achievement in 2024 after stopping transmission in Venezuela and Brazil.

What Did HHS Secretary Robert F Kennedy Jr And CDC Chief Dr Erica Schwartz Say?

Also read: US Loses Measles Elimination Status After 26 Years: What Does It Mean?

After PAHO's announcement, US Health and Human Services Secretary Robert F. Kennedy Jr and Centers for Disease Control and Prevention (CDC) Director Dr Erica Schwartz issued separate statements.

Kennedy said the administration would continue working to control outbreaks and restore the country's elimination status.

"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," he said in a statement. He also expressed his support for vaccination, adding, "I continue to recommend MMR vaccination as the most effective way to prevent measles."

Kennedy attributed gaps in childhood immunisation to disruptions during the COVID-19 pandemic which affected routine vaccination programmes in the US and other countries.

He also said that approximately $100 million in additional CDC funding has been provided since August to strengthen measles prevention and outbreak response. The funding is intended to support state and local health departments, improve surveillance and help close vaccination gaps.

CDC Director Dr Schwartz said the loss of the designation would not change the agency's approach to controlling the disease.

"The measles elimination designation is not what protects Americans. Vaccination does. We know where transmission is occurring and we've invested $100 million in state and local health departments to reach those communities," she said.

"Losing a designation doesn't mean we abandon an evidence-based approach. It means we remain focused on stopping outbreaks."

Also read: RFK Jr's Vaccine Controversy: What His Samoa Trip Has To Do With 83 Measles Deaths

Measles Resurgence In The Americas

The latest PAHO figures highlight the scale of the resurgence. The region recorded more than four times as many confirmed measles cases by November 13, 2026 as during the corresponding period in 2025.

Mexico has reported more than 13,900 confirmed cases so far in 2026, the highest annual total since the 1989-90 epidemic. The US has recorded more than 5,400 cases and 10 deaths, its highest in more than 35 years. Bolivia has reported more than 100 cases.

Amid the resurgence, a CDC report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.

Measles is among the most contagious infectious diseases. One infected person can transmit the virus to as many as 18 people who are susceptible to infection.

The disease typically causes fever, cough, a runny nose, red and watery eyes, followed by a characteristic skin rash. However, it can also lead to serious complications, including pneumonia, brain inflammation (encephalitis), blindness and death. It can also weaken the immune system for months after infection.

Can The Countries Regain Measles Elimination Status?

PAHO expects the US, Mexico and Bolivia to submit plans outlining how they plan to interrupt transmission and strengthen measles vaccination and surveillance.

The organisation has called on countries across the Americas to achieve and maintain at least 95% coverage with both doses of the measles vaccine.

The MMR vaccine, which protects against measles, mumps and rubella, remains the most effective way to prevent measles.

End of Article